Stifel analyst Alex Thompson raised the firm’s price target on Apogee Therapeutics to $95 from $46 and keeps a Buy rating on the shares following the “positive” Phase 1 update for APG777. Not only does the firm believe that today’s updates drive an increase in the odds of success for APG777 in atopic dermatitis, or AD, but it also believes the potential for maintenance dosing every six months “should drive greater market share,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APGE:
- Apogee Therapeutics Unveils Promising APG777 Phase 1 Data
- Apogee Therapeutics Announces Breakthrough Phase 1 Results
- Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
- Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
